ASCO 2022

At Ontada, we believe that data and insights are our best opportunity to understand the path towards achieving health equity. It is a focus of ours to drive more equitable access to diagnoses, therapies, and care and to improve outcomes among diverse patients.

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting theme – “Advancing Equitable Cancer Care Through Innovation” – reflects this same commitment to providing better care for all patients and recognizes that to keep moving forward, we must be innovative in our approach.

Some relevant innovations currently underway at Ontada include capturing more social determinants of health (SDOH) insights from iKnowMedSM, our oncology-focused electronic health record. We’re also leveraging third-party sources to enrich our datasets, enabling us to link our patient records with additional economic and social indicators such as income, education, occupation, household size, etc., to help our partners tackle key questions regarding patients’ access to care and treatment. These innovations will continue to bolster our research efforts.

Achieving health equity cannot be done by any single entity. It was exciting to be face-to-face with many of our partners across the industry during this year’s meeting and to engage in meaningful discussions about how we can make strides together towards delivering better outcomes for all patients.

Below, you’ll find summaries of our abstracts from this year’s ASCO Annual Meeting.

ASCO 2022 | Ontada abstracts

Impact of Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium
The MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) Consortium clinical trial platform aims to advance the use of precision medicine in non-small cell lung cancer (NSCLC) patients. “Protocol 2” is evaluating the patient and tissue journey of newly diagnosed lung cancer patients. As timely patient accrual to oncology clinical trials is a known practice challenge, this abstract aimed to assess the impact of incorporating a clinical pharmacist to provide remote clinical services in support of Protocol 2 enrollment.

Predictors of Biomarker Testing Among Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
The MYLUNG Consortium pragmatic study (“Protocol 1”) assessed real-world biomarker testing rates for mNSCLC within The US Oncology Network of over 1,000 providers. This study examines patient factors associated with rates of biomarker testing.

Blood Monocyte and Lymphocyte Counts Versus Patient Outcomes in Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitor Therapy: Real-World Data of 12,416 patients.
Immune checkpoint inhibitors (ICPi) are now commonly used in NSCLC treatment. Although there some predictive tests to guide therapeutic decision making regarding their use, blood monocyte, lymphocyte counts, or their ratio were explored as potential predictors to inform clinical utility of these agents.

Characteristics, blood counts, treatments, and clinical outcomes of 3,022 patients (Pts) with polycythemia vera (PV) treated in U.S. community practices.
Cytoreduction with hydroxyurea (HU) is the recommended first-line (1L) treatment for high-risk PV (age ≥60 y or history of thrombosis), but many patients have a suboptimal response on HU. The objective of this study was to describe characteristics, blood counts, treatments, and clinical outcomes among patients with PV in a large network of US community oncology practices.

Real-World Progression-Free and Overall Survival for Patients with Advanced Ovarian Cancer Utilizing PARP Inhibitor Second-Line Maintenance Therapy vs Active Surveillance
Ovarian cancer (OC) is the fifth leading cause of cancer death among women. Poly(ADP-ribose) polymerase inhibitors (PARPis) are recommended following response to second-line (2L) chemotherapy, based on results from clinical trials demonstrating their ability to extend progression-free survival (PFS), the time between chemotherapy and relapse, in this patient population. This study presents recent estimates of real-world PFS and overall survival (OS) for patients on 2L PARPi maintenance therapy versus active surveillance.

Real-world (RW) Treatment Patterns and Clinical Outcomes for Chemotherapy-Based Regimens in First Line (1L) MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)
Until the global approval of pembrolizumab for the treatment of first line (1L) MSI-H/dMMR metastatic CRC (mCRC), newly diagnosed patients were managed with standard of care treatments like chemotherapy with or without an EGFR/VEGF inhibitor. This study assessed the real-world standard of care treatment patterns and outcomes among 1L MSI-H/dMMR mCRC patients.

Additional information about our presence at ASCO can be found here.